Biomarkers and the genetics of early neoplastic lesions

Cancer Biomarkers

Volumn 9, Issue 1-6, 2011, Pages 41-64

  Srivastava, Sudhir ^a   Grizzle, William E ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

aneuploidy; angiogenesis; biomarkers; caretakers; clonal selection; deletions; dysplasia; epigenetics; exosomes; gatekeepers; immunoregulation; insertions; Intraepithelial neoplasia; landscapers; LOCDIR; methylation; microsatellite instability; mismatch repair genes; mutations; oncogenes; suppressor genes; translocations; tumor associated fibroblasts; validation; viral insertions

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; MICRORNA; PROTEIN BCL 2; PROTEIN P16; PROTEIN P19; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA;

ADENOMA; ADVANCED CANCER; ANEUPLOIDY; ANGIOGENESIS; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER GENETICS; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CHROMATIN STRUCTURE; CHROMOSOME ABERRATION; CHROMOSOME DUPLICATION; CHROMOSOME TRANSLOCATION; CHRONIC CHOLECYSTITIS; CHRONIC GASTRITIS; CHRONIC PANCREATITIS; COLON ADENOMA; COLORECTAL CANCER; CPG ISLAND; DENDRITIC CELL; DNA REPAIR; DNA SYNTHESIS; EARLY CANCER; EARLY DIAGNOSIS; ENDOMETRIUM HYPERPLASIA; ENTERITIS; EPIGENETICS; EXOSOME; FRAMESHIFT MUTATION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENOME ANALYSIS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH THROUGHPUT SCREENING; HUMAN; INHIBITION KINETICS; INTRADUCTAL CARCINOMA; LIVER CIRRHOSIS; METASTASIS; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; MYOFIBROBLAST; OVARY CANCER; PHENOTYPE; POLYMERASE CHAIN REACTION; PRECANCER AND CANCER-IN-SITU; PRIORITY JOURNAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN PROCESSING; PROTEIN STABILITY; REGULATORY MECHANISM; RNA DEGRADATION; RNA TRANSLATION; TARGETED GENE REPAIR; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

ANIMALS; HUMANS; NEOPLASM STAGING; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 82955193275     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0204     Document Type: Article

References (191)

1. P. Holowaty, A. B. Miller, T. Rohan and T. To, Natural history of dysplasia of the uterine cervix [see comments], J Natl Cancer Inst 91 (1999), 252-258.
2. L. G. Koss, Epidermoid carcinoma of the uterus, cervix and related precancerous lesions in: LG Koss's Diagnostic Cytology and its Histopathologic Bases, (3rd edition), Philadelphia: J. B. Lippincott Company, 1979, pp. 285-375.
3. C. W. Boone, G. J. Kelloff and V. E. Steele, Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy, Cancer Res 52 (1992), 1651-1659.
4. W. E. Grizzle, S. Srivastava and U. Manne, The biology of incipient, pre-invasive and intraepithelial neoplasia, Cancer Biomark 9 (2011), 21-39.
5. G. Deng, Y. Lu, G. Zlotnikov, A. D. Thor and H. S. Smith, Loss of heterozygosity in normal tissue adjacent to breast carcinomas, Science 274 (1996), 2057-2059.
6. M. C. Lin, G. L. Mutter, P. Trivijisilp, K. A. Boynton, D. Sun and C. P. Crum, Patterns of allelic loss (LOH) in vulvar squamous carcinomas and adjacent noninvasive epithelia, Am J Pathol 152 (1998), 1313-1318.
7. M. Korc, Smad4: gatekeeper gene in head and neck squamous carcinoma, J Clin Invest 119(11) (2009), 3208-3212.
8. S. Bornstein, R. White, S. Malkoski, M. Oka, G. Han, T. Cleaver, D. Reh, P. Andersen, N. Gross, S. Olson, C. Deng, S. -L. Lu and X. -J. Wang, Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation, J Clin Invest 119 (2009), 3408-3419.
9. L. A. Loeb, A mutator phenotype in cancer, Cancer Res 61 (2001), 3230-3239.
10. G. Ling, A. Persson, B. Berne, M. Uhlén, J. Lundeberg and F. Ponten, Persistent p53 mutations in single cells from normal human skin, Am J Pathol 159 (2001), 1247-1253.
11. H. B. Burke, Outcome prediction and the future of the TNM staging system, J Natl Cancer Inst 96(19) (2004), 1408-1409.
12. E. R. Fearon and B. A. Vogelstein, A genetic model for colorectal carcinogenesis, Cell 61 (1990), 579-567.
13. C. Shanmugam, V. R. Katkoori, N. C. Jhala, W. E. Grizzle, G. P. Siegal and U. Manne, p53 Nuclear accumulation and bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behavior, J Histochem Cytochem 56(3) (2008), 305-312. PMCID: PMC2324183.
14. W. E. Grizzle, D. Shibata, U. Manne, R. B. Myers and A. R. Frost, Molecular and histopathologic changes in the development of colorectal neoplasia, in: Molecular Pathology of Early Cancer, S. Srivastava, D. E. Henson and A. Gazdar, eds, IOS Press, Amsterdam, Netherlands, Chapter 10, 1999, pp. 135-170.
15. E. P. Sandgren, Mouse models of exocrine pancreatic cancer, in: Pancreatic Cancer, D. D. Hoff, D. B. Evans and R. H. Hruban, eds, Jones and Bartlett Publishers, Sudbury, Massachusetts,Chapter 6, 2005, pp. 87-100.
16. A. J. Aguirre, N. Bardessy, M. Sinha, L. Lopez, D. A. Tuveson, J. Horner, M. S. Redston and R. A. DePinho, Activated Kras and Ink4a/Arf deficiency cooperate to producemetastatic pancreatic ductal adenocarcinoma, Genes & Development 17 (2003), 3112-3126.
17. A. S. Jonason, S. Kunala, G. J. Price, R. J. Restifo, H. M. Spinelli, J. A. Persing, D. J. Leffell, R. E. Tarone and D. E. Brash, Frequent clones of p53-mutated keratinocytes in normal human skin, Proc Natl Acad Sci U S A 93(24) (1996), 14025-14029.
18. D. Hanahan and R. A. Weinberg, The hallmarks of cancer: A review 100 (2000), 57-70.
19. E. R. Fearon, S. R. Hamilton and B. Vogelstein, Clonal analysis of human colorectal tumors, Science 238 (1987), 193-197.
20. C. Caldas, Molecular assessment of cancer, Bmj 316 (1998), 1360-1363.
21. R. A. Weinberg, Cancer: A genetic disorder. Chapter 1 in TheMolecular Basis of Cancer, in: Elsevier Press, (3rd edition), J. Mendelsohn, P. M. Howley, M. A. Israel, J. W. Gray and C. B. Thompson, eds, 2008, pp. 3-9.
22. L. A. Loeb, C. F. Springgate and N. Battula, Errors in DNA replication as a basis of malignant changes, Cancer Res 34 (1974), 2311-2321.
23. L. A. Loeb, Transient expression of a mutator phenotype in cancer cells [comment], Science 277 (1997), 1449-1450.
24. C. R. Boland and L. Ricciardiello, How many mutations does it take to make a tumor? [comment], Proc Natl Acad Sci U S A 96 (1999), 14675-14677.
25. I. Tomlinson and W. Bodmer, Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog, Nat Med 5 (1999), 11-12.
26. P. C. Nowell, The clonal evolution of tumor cell populations, Science 194 (1976), 23-28.
27. D. P. Slaughter, H. W. Southwick andW. Smejkal, "Field cancrization" in oral stratified squamous epithelium, Cancer 6 (1953), 963-968.
28. M. J. Bissell and D. Radisky, Putting tumours in context, Nature 1 (2001), 46-54.
29. G. R. Cunha, S. W. Hayward, R. Dahiya and B. A. Foster, Smooth muscle-epithelial interactions in normal and neoplastic prostatic development, Acta Anat 155 (1996), 63-72.
30. S. W. Hayward, G. D. Grossfeld, T. D. Tlsty and G. R. Cunha, Genetic and epigenetic influences in prostatic carcinogenesis (review), Int J Oncol 13 (1998), 35-47.
31. U. Manne, H. L. Weiss and W. E. Grizzle, Bcl-2 Expression is Associated with Improved Prognosis in Patients with Distal Colorectal Adenocarcinomas, Int J Cancer 89(5) (2000), 423-430.
32. G. M. Callagy, P. D. Pharoah, S. E. Pinder, F. D. Hsu, T. O. Nielsen, J. Ragaz, I. O. Ellis, D. Huntsman and C. Caldas, Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index, Clin Cancer Res 12 (2006), 2468.
33. G. Tonon andK. C. Anderson, Lymphoma/Myeloma. Chapter 26 in The Molecular Basis of Cancer, in: Elsevier Press, (3rd edition), J. Mendelsohn, P. M. Howley, M. A. Israel, J. W. Gray and C. B. Thompson, eds, 2008, pp. 351-359.
34. R. B. Myers, D. Oelschlager, S. Srivastava and W. E. Grizzle, Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas, Prostate 25(5) (1994), 243-248.
35. P. J. Morin, B. Vogelstein and K. W. Kinzler, Apoptosis and APC in colorectal tumorigenesis, Proc Natl Acad Sci U S A 93 (1996), 7950-7954.
36. R. A. Weinberg, How cancer arises, Sci Am 275 (1996), 62-70.
37. R. E. Hollingsworth and W. H. Lee, Tumor suppressor genes: new prospects for cancer research [see comments], J Natl Cancer Inst 83 (1991), 91-96.
38. L. A. Liotta, P. S. Steeg and W. G. Stetler-Stevenson, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation, Cell 64 (1991), 327-336.
39. T. Kalebic, S. Garbisa, B. Glaser and L. A. Liotta, Basement membrane collagen: degradation by migrating endothelial cells, Science 221 (1991), 281-283.
40. T. Kalebic, J. E. Williams, J. E. Talmadge, C. S. Kao-Shan, B. Kravitz, K. Locklear, G. P. Siegal, L. A. Liotta,M. E. Sobel and P. S. Steeg, A novel method for selection of invasive tumor cells: derivation and characterization of highly metastatic K1735 melanoma cell lines based on in vitro and in vivo invasive capacity, Clin Exp Metastasis 6 (1988), 301-318.
41. V. P. Terranova, C. N. Rao, T. Kalebic, I. M. Margulies and L. A. Liotta, Laminin receptor on human breast carcinoma cells, Proc Natl Acad Sci U S A 80 (1983), 444-448.
42. J. Folkman, Angiogenesis inhibitors generated by tumors, Mol Med 1 (1995), 120-122.
43. R. B. Myers, R. F. Meredith, J. Schlom, A. F. LoBuglio, A. J. Bueschen, R. H. Wheeler, C. R. Stockard and W. E. Grizzle, Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas, J Urol 152(1) (1994), 243-246.
44. M. Macaluso, M. G. Paggi and A. Giordano, Genetic and epigenetic alterations as hallmarks of the intricate road to cancer, Oncogene 22 (2003), 6472-6478.
45. E. Solomon, J. Borrow and A. D. Goddard, Chromosome aberrations and cancer, Science 254 (1991), 1153-1160.
46. R. Montironi, R. Pomante, P. Colanzi, D. Thompson, P. W. Hamilton and P. H. Bartels, Diagnostic distance of high grade prostatic intraepithelial neoplasia from normal prostate and adenocarcinoma, J Clin Pathol 50 (1997), 775-782.
47. R. B. Fitzgerald and G. Triadfilopoulos, Recent developments in the molecular characterization of Barrett's esophagus, Dig Dis 16 (1998), 63-80.
48. M. A. Micale, D. W. Visscher, S. E. Gulino and S. R. Wolman, Chromosomal aneuploidy in proliferative breast disease, Hum Pathol 25 (1994), 29-35.
49. J. O. Lindberg, R. B. Stenling and J. N. Rutegard, DNA aneuploidy as a marker of premalignancy in surveillance of patients with ulcerative colitis, Br J Surg 86 (1999), 947-950.
50. C. L. Andersen, C. Wiuf, M. Kruhøffer, M. Korsgaard, S. Laurberg and T. F. ørntoft, Frequent occurrence of uniparental disomy in colorectal cancer, Carcinogenesis 28(1) (2007), 38-48.
51. C. S. Walsh, S. Ogawa, D. R. Scoles, C. W. Miller, N. Kawamata, S. A. Narod, H. P. Koeffler and B. Y. Karlan, Genomewide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas, 14(23) (2008), 7645-7651.
52. S. Lee, J. Jeong, T. Majewski, S. E. Scherer, M. -S. Kim, T. Tuziak, K. S. Tang, K. Baggerly, H. B. Grossman, J. -H. Zhou, L. Shen, J. Bondaruk, S. S. Ahmed, S. Samanta, P. Spiess, X. Wu, S. Filipek, D. McConkey, M. Bar-Eli, J. -P. Issa,W. F. Benedict and B. Czerniak, Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia, Proc Natl Acad Sci U S A 104(34) (2007), 13732-13737
53. M. -S. Kim, J. Jeong, T. Majewski, A. Kram, D. -S. Yoon, R. - D. Zhang, J. -Z. Li, K. Ptaszynski, T. C. Kuang, J. -H. Zhou, U. G. Sathyanarayana, T. Tuziak, D. A. Johnston, H. B. Grossman, A. F. Gazdar, S. E. Scherer, W. F. Benedict and B. Czerniak, Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasia, Laboratory Investigation 86 (2006), 175-190.
54. B. W. Schafer, Emerging roles for PAX transcription factors in cancer biology, Gen Physiol Biophys 17 (1998), 211-224.
55. E. T. Stuart, R. Haffner, M. Oren and P. Gruss, Loss of p53 function through PAX-mediated transcriptional repression, Embo J 14 (1995), 5638-5645.
56. A. Quintás-Cardama, J. Cortes and H. Kantarjian, Biology of chronic and acute myeloid leukemia, Chapter 28 in The Molecular Basis of Cancer, in: Elsevier Press, (3rd edition), J. Mendelsohn, P. M. Howley, M. A. Israel, J. W. Gray and C. B. Thompson, eds, 2008, pp. 371-383.
57. J. D. R. Reimann and C. D. M. Fletcher, Soft-tissue sarcomas. Chapter 37 in The Molecular Basis of Cancer, in: Elsevier Press, (3rd edition), J. Mendelsohn, P. M. Howley, M. A. Israel and J. W. Gray, eds, Thompson CB, 2008, pp. 471-477.
58. S. A. Tomlins, D. R. Rhodes, S. Perner, S. M. Dhanasekaran, R. Mehra, X. W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, C. Lee, J. E. Montie, R. B. Shah, K. J. Pienta, M. A. Rubin and A. M. Chinnaiyan, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, Science 310 (2005), 644-648.
59. S. A. Tomlins, B. Laxman, S. Varambally, X. Cao, J. Yu, B. E. Helgeson, Q. Cao, J. R. Prensner, M. A. Rubin, R. B. Shah, R. Mehra and A. M. Chinnaiyan, Role of the TMPRSS2-ERG gene fusion in prostate cancer, Neoplasia 10(2) (2008), 177-188.
60. R. K. Nam, L. Sugar, W. Yang, S. Srivastava, L. H. Klotz, L. - Y. Yang, A. Stanimirovic, E. Encioiu, M. Neill, D. A. Loblaw, J. Trachtenberg, S. A. Narod and A. Seth, Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer, British Journal of Cancer 97(12) (2007), 1690-1695.
61. M. Soda, Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S. Fujiwara, H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama and H. Mano, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature 448(7153) (2007), 561-566.
62. A. S. Jonason, S. Kunala, G. J. Price, R. J. Restifo, H. M. Spinelli, J. A. Persing, D. J. Leffell, R. E. Tarone and D. E. Brash, Frequent clones of p53-mutated keratinocytes in normal human skin, Proc Natl Acad Sci U S A 93(24) (1996), 14025-14029.
63. N. Honnavara, S. M. Ananthaswamy, P. C. Loughlin, R. L. Evans, S. E. Ullrich and M. L. Kripke, Sunlight and skin cancer: inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens, Nature Medicine 3(5) (1997), 510-526.
64. C. Campbell, A. G. Quinn, Y. -S. Ro, B. Angus and J. L. Rees, P53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin, J Invest Dermatol 100 (1993), 746-748.
65. K. W. Kinzler and B. Vogelstein, Gatekeepers and caretakers, Nature 386 (1997), 761-763.
66. N. Levitt and I. Hickson, Caretaker tumor suppressor genes that defend genome integrity, Trends in Molecular Medicine 8 (2002), 179-186.
67. D. van Gent, J. Hoeijkmakers and R. Kanaar, Chromosomal stability and the DNAdouble-stranded break connection, Nature Reviews Genetics 2 (2001), 196-206.
68. J. Gu, M. R. Spritz, H. Zhao, J. Lin, H. B. Grossman, C. P. Dinney and X. Wu, Roles of tumor suppressor and telomere maintenance genes in cancer and aging - an epidemiological study, Carcinogenesis 26 (2005), 1741-1747.
69. D. P. van Heemst, den Reijner and R. Westendorp, On the role of caretakers and gatekeepers, European Journal of Cancer 43 (2007), 2144-2152.
70. M. A. Nowak, N. L. Komarova, A. Sengupta, P. V. Jallepalli, I. -M. Shih, B. Vogelstein and C. Lengauer, The role of chromosomal instability in tumor initiation, Proc Natl Acad Sci U S A 99 (2002), 16226-16231.
71. M. Goggins, M. Schutte, J. Lu et al. , Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas, Cancer Res 56 (1996), 5360-5364.
72. J. J. Chen,D. Silver, S. Cantor, D. M. Livingston and R. Scully, BRCA1, BRCA2, and Rad 51 operate in a common DNA damage response pathway, Cancer Res 59(7 Suppl) (1999), 1752s-1756s.
73. J. Feunteun, Breast cancer and genetic instability: the molecules behind the scenes, Mol Med Today 4 (1998), 263-267.
74. G. Rotman and Y. Shiloh, ATM: from gene to function, Hum Mol Genet 7 (1998), 1555-1563.
75. K. Ito, A. C. -B. Lim, M. Salto-Tellez, L. Motoda, M. Osato, L. Shuye, H. Chuang, C. W. L. Lee, D. C. -C. Voon, J. K. W. Koo, H. Wang, H. Fukamachi and Y. Ito, RUNX3 attenuates β-catenin/T cell factors in intestinal tumorigenesis, Cancer Cell 14 (2008), 226-237.
76. V. Pistoia, C. Cocco and I. Airoldi, Interleukin-12 receptor β2: From cytokine receptor to gatekeeper gene in human B-cell malignancies, J Clin Oncol 27 (2009), 4809-4816.
77. J. Campisi, Aging tumor suppression and cancer: a high wire act, Mechanisms of Ageing and Development 26 (2005), 51-58.
78. S. Frank, Somatic mutation: Early cancer steps depend on tissue architecture, Current Biology 13 (2003), 261-263.
79. F. Michor, Dynamics of cancer progression, Nature Reviews Cancer 4 (2004), 197.
80. K. Maceod, Tumor suppressor genes, Current Opinion in Genetics and Development 10 (2000), 81-93.
81. T. Borg, It's the matrix: ECM, proteases and cancer, Am J Pathol 164 (2004), 1141-1142.
82. J. Lawler,W. -M. Miao,M. Duquette, N. Bouck, R. T. Bronson and R. O. Hynes, Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice, Am J Pathol 159(5) (2001), 1949-1956.
83. B. Mintz and K. Illmensee, Normal genetically mosaic mice produced from malignant teratocarcinoma cells, Proc Natl Acad Sci U S A 72 (1975), 3585.
84. Y. Ionov, M. A. Peinado, S. Malkhosyan, S. Shibata and M. Perucho, Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis, Nature 363 (1993), 5658-5561.
85. W. Dietmaier, S. Wallinger, T. Bocker, F. Kullmann, R. Fishel and J. Rüschoff, Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression, Cancer Res 57 (1997), 4749-4756.
86. C. R. Boland, S. N. Thibodeau, S. R. Hamilton, D. Sidaransky, J. R. Eshleman, R. W. Burt, S. J. Meltzer, M. A. Rodriguez- Bigas, R. Fodde, G. N. Ranzani and S. Srivstava, A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Res 58 (1998), 5248-5257.
87. M. Aarnio, R. Sankila, E. Pukkala, R. Salovaara, L. A. Aaltonen, A. de la Chapelle, P. Peltomäki, J. P. Mecklin and H. J. Järvinen, Cancer risk inmutation carriers ofDNA-mismatchrepair genes, Int J Cancer 81 (1999), 214-218.
88. L. Mao, J. S. Lee, Y. H. Fan, J. Y. Ro, J. G. Batsakis, S. Lippman, W. Hittelman and W. K. Hong, Frequent microsatellitealterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment, Nat Med 2 (1996), 682-685.
89. S. N. Thibodeau, G. Bren and D. Schaid, Microsatellite instability in cancer of the proximal colon, Science 260 (1993), 816-819.
90. A. Bird, DNA methylation patterns and epigenetic memory, Genes DEV 16 (2002), 6.
91. A. P. Bird and A. P. Wolffe, Methylation-induced repressionbelts, braces, and chromatin, Cell 99 (1999), 451.
92. A. P. Bird, CpG-rich islands and the function of DNA methylation. [Review], Nature 321 (1986), 209.
93. P. L. Jones and A. P. Wolffe, Relationships between chromatin organization and DNA methylation in determining gene expression, Semin Cancer Biol 9 (1999), 339-347.
94. J. G. Herman, A. Merlo, L. Mao, R. G. Lapidus, J. P. Issa, N. E. Davidson, D. Sidransky and S. B. Baylin, Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers, Cancer Res 55 (1995), 4525-4530.
95. P. A. Jones, The DNA methylation paradox, Trends Genet 15 (1999), 34-37.
96. S. A. Belinsky, K. J. Nikula, W. A. Palmisano, R. Michels, G. Saccomanno, E. Gabrielson, S. B. Baylin and J. G. Herman, Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis, Proc Natl Acad Sci U S A 95 (1998), 11891-11896.
97. E. Dulaimi, I. I. de Caceres, R. G. Uzzo, T. Al-Saleem, R. E. Greenberg, T. J. Polascik, J. S. Babb, W. E. Grizzle and P. Cairns, Promoter hypermethylation profile of kidney cancer, Clin Cancer Res 10 (2004), 3973-3979.
98. J. M. Jones, X. S. Cui, D. Medina and L. A. Donehower, Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model, Cell Growth Differ 10 (1999), 213-222.
99. P. A. Jones and M. L. Gonzalgo, AlteredDNAmethylation and genome instability: a new pathway to cancer? [comment], Proc Natl Acad Sci U S A 94 (1997), 2103-2105.
100. J. Brooks, P. Cairns and A. Zeleniuch-Jacquotte, Promoter methylation and the detection of breast cancer, Cancer Causes Control 20(9) (2009), 1539-1550.
101. I. I. de Caceres and P. Cairns, Methylated DNA sequences for early cancer detection, molecular classification and chemotherapy response prediction, Clin Transl Oncol 9(7) (2007), 429-437.
102. G. Nguyen-Ba and P. Vasseur, Epigenetic events during the process of cell transformation induced by carcinogens (review), Oncol Rep 6 (1999), 925-932.
103. S. A. Belinsky, J. H. Schiller and C. A. Stidley, DNA methylation biomarkers to assess therapy and chemoprevention for non-small cell lung cancer, Nutr Rev 66(Suppl 1) (2008), S24-S26.
104. M. Tessema, Y. Y. Yu, C. A. Stidley, E. O. Machida, K. E. Schuebel, S. B. Baylin and S. A. Belinsky, Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers, Carcinogenesis 30(7) (2009), 1132-1138.
105. A. Potapova, A. M. Hoffman, A. K. Godwin, T. Al-Saleem and P. Cairns, Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer, Cancer Res 68(4) (2008), 998-1002.
106. A. Ravaioli, F. Monti, M. M. Regan, F. Maffini, M. G. Mastropasqua, V. Spataro, M. Castiglione-Gertsch, I. Panzini, L. Gianni, A. Goldhirsch, A. Coates, K. N. Price, B. A. Gusterson and G. Viale, On behalf of the International Breast Cancer Study Group. p27 and SKp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer, Annals of Oncology 19 (2008), 660-668.
107. M. Pagano, S. W. Tam, A. M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P. R. Yew, G. F. Draetta andM. Rolfe, Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27, Science 269(5224) (1995), 631-632.
108. C. Ginestier, M. H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C. G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M. S. Wicha and G. Dontu, ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcomes, Cell Stem Cell 1 (2007), 555-567.
109. H. Wang, N. Shao, Q. M. Ding, J. -Q. Cui, E. S. R. Reddy and V. N. Rao, BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases, Oncogene 15 (1997), 143-157.
110. F. J. Slack and J. B. Weidhaas,MicroRNAin cancer prognosis, N Engl J Med 359(25) (2008), 2720-2722.
111. K. Chen and N. Rajewsky, The evolution of gene regulation by transcription factors andmicroRNAs, Nature Reviews Genetics 8 (2007), 93-103.
112. A. E. Williams, Functional aspects of animal microRNAs, Cell Mol Life Sci 65(4) (2008), 545-562.
113. A. Eulalio, E. Huntzinger, T. Nishihara, J. Rehwinkel, M. Fauser and E. Izaurralde, Deadenylation is a widespread effect of miRNA, RNA 15(1) (2009), 21-32.
114. J. Lu, G. Getz, E. A. Miska, E. Alvarez-Saavedra, J. Lamb, D. Peck, A. Sweet-Cordero, B. L. Ebert, R. H. Mak, A. A. Ferrando, J. R. Downing, T. Jacks, H. R. Horvitz and T. R. Golub, MicroRNA expression profiles classify human cancers, Nature 435 (2005), 834-838.
115. G. M. Arndt, L. Dossey, L. M. Cullen, A. Lai, R. Druker, M. Eisbacher, C. Zhang, N. Tran, H. Fan, K. Retzlaff, A. Bittner and M. Raponi, Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer, BMC Cancer 9 (2009), 374.
116. K. P. Porkka, M. J. Pfeiffer, K. K. Waltering, R. L. Vessella, T. L. J. Tammela and T. Visakorpi,MicroRNA expression profiling in prostate cancer, Cancer Res 67(13) (2007), 6130-6135.
117. S. W. Blume, D. M. Miller, V. Guarcello, K. Shrestha, Z. Meng, R. C. Snyder, W. E. Grizzle, J. M. Ruppert, G. L. Gartland, C. R. Stockard, D. E. Jones and P. Emanuel, Inhibition of tumorigenicity by the 5'-untranslated RNA of the human c-myc P0 transcript, Exp Cell Res 288(1) (2003), 131-142.
118. H. Choi, N. L. Jackson, D. R. Shaw, P. D. Emanuel, Y. L. Liu, A. Tousson, Z. Meng and S. W. Blume, mrtl-A translation/ localization regulatory protein encoded within the human c-myc locus and distributed throughout the endoplasmic and nucleoplasmic reticular network, J Cell Biochem 105 (2008), 1092-1108.
119. Z. Meng, N. L. Jackson, H. Choi, P. H. King, P. D. Emanuel and S. W. Blume, Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanisms of psychological variability and pathological dysregulation of IGF-IR translational control in human breast cells, J Cell Physiol 217 (2008), 172-183.
120. L. E. Littlepage, M. Egeblad and Z. Werb, The tumor microenvironment in cancer progression, in: The Molecular Basis of Cancer, (3rd edition), Elsevier Press, J. Mendelsohn, P. M. Howley, M. A. Israel, J. W. Gray and C. B. Thompson, eds, pp. 229-239.
121. H. -G. Zhang and W. E. Grizzle, Aging, immunity and tumor susceptibility, Immunol Allergy Clin N Am 23 (2003), 83-102.
122. W. E. Grizzle, J. D. Mountz, P. A. Yang et al. , BSC recombinant inbred mice represent a novel T cell-mediated immune response tumor model, Int J Cancer 101(3) (2002), 270-279.
123. C. E. Lewis and J. W. Pollard, Distinct role of macrophages in different tumor microenvironments, Cancer Res 66(2) (2006), 605-612.
124. S. Goswami, E. Sahai, J. B. Wyckoff, M. Cammer, D. Cox, F. J. Pixley, E. R. Stanley, J. E. Segall and J. S. Condeelis, Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop, Cancer Res 65(12) (2005), 5278-5283.
125. K. L. Schwertfeger, W. Xian, A. M. Kaplan, S. H. Burnett, D. A. Cohen and J. M. Rosen, A critical role for the inflammatory response in amousemodel of preneoplastic progression, Cancer Res 66(11) (2006), 5676-5685.
126. B. Al-Sarireh and O. Eremin, Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth, J R Coll Surg Edinb 45 (2000), 1-16.
127. J. J. W. Chen, P. -L. Yao, A. Yuan, T. -M. Hong, C. -T. Shun, M. -L. Kuo, Y. -C. Lee and P. -C. Yang, Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer, Clin Cancer Res 9 (2003), 729-737.
128. M. Iero, R. Valenti, V. Huber, P. Filipazzi, G. Parmiani, S. Fais and L. Rivoltini, Tumour-released exosomes and their implications in cancer immunity, CellDeathDiffer 15 (2008), 80-88.
129. H. -G. Zhang andW. E. Grizzle, Exosomes and cancer: a newly described pathway of immune suppression, Clin Cancer Res 17(5) (2011), 959-964.
130. R. M. Johnstone, Exosomes biological significance: a concise review, Blood Cells Mol Dis 36 (2006), 315-321.
131. H. -G. Zhang, C. Liu, K. Su, S. Yu, L. Zhang, S. Zhang, J. Wang, X. Cao, W. Grizzle and R. P. Kimberly, A membrane form of TNF-α presented by exosomes delays T cell activation-induced cell death, J Immunol 176 (2006), 7385-7393.
132. G. -J. Wang, Y. Liu, A. Qin, S. V. Shah, Z. -B. Den, X. Xiang, Z. Chang, C. Liu, J. Wang, L. Zhang,W. E. Grizzle and H. -G. Zhan, Thymus exosomes-like particles induce regulatory T cells, J Immunol 181 (2008), 5242-5248.
133. C. Liu, S. Yu, K. Zinn, J. Wang, L. Zhang, Y. Jia, J. C. Kappes, S. Barnes, R. P. Kimberly, W. E. Grizzle and H. G. Zhang, Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function, J Immunol 176 (2006), 1375-1385.
134. A. F. Olumi, G. D. Grossfeld, S. W. Hayward, P. R. Carroll, T. D. Tlsty and G. R. Cunha, Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium, Cancer Res 59 (1999), 5002-5011.
135. C. Kuperwasser, T. Chavarria, M. Wu, G. Magrane, J. W. Gray, L. Carey, A. Richardson and R. A. Weinberg, Reconstruction of functionally normal and malignant human breast tissues in mice, Proc Natl Acad Sci U S A 101(14) (2004), 4966-4971.
136. V. M. Weaver, O. W. Petersen, F. Wang, C. A. Larabell, P. Briand, C. Damsky and M. J. Bissell, Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies, J Cell Biol 137(1) (1997), 231-245.
137. M. Tamm, M. Bihl, O. Eickelberg, P. Stulz, A. P. Perruchoud andM. Roth, Hypoxia-induced interleukin-6 and interleukin- 8 production is mediated by platelet-activating factor and platelet-derived growth factor in primary human lung cells, Am J Respir Cell Mol Biol 19(4) (1998), 653-661.
138. I. C. Anderson, S. E. Mari, R. J. Broderick, B. P. Mari and M. A. Shipp, The angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast cocultures, Cancer Res 60 (2000), 269-272.
139. E. V. Bobrovnikova-Marjon, P. L. Majon, O. Barbash, D. L. Vander Jagt and S. F. Abcouwer, Expression of angiogenic factors vascular endothelial growth factor and interleukin- 8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-?B and activating protein-1, Cancer Res 64 (2004), 4858-5869.
140. J. M. Smith, P. A. Johanesen, M. K. Wendt, D. G. Binion and M. B. Dwinell, CXCL12 activation of CXCR4 regulates mucosal host defense through stimulation of epithelial cell migration and promotion of intestinal barrier integrity, Am J Physiol Gastrointest Liver Physiol 288 (2005), G316-G326.
141. T. Koshiba, R. Hosotani, Y. Miyamoto, J. eIda, S. Tsuji, S. Nakajima, M. Kawaguchi, H. Kobayashi, R. Doi, T. Hori, N. Fujii and M. Imamura, Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor, Clin Cancer Res 6 (2000), 3530-3535.
142. S. Singh, U. P. Singh, W. E. Grizzle and J. W. Lillard Jr. , CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion, Laboratory Investigation (2004), 1-11.
143. K. Ohuchida, K. Mizumoto, M. Murakami, L. -W. Qian, N. Sato, E. Nagai, K. Matsumoto, T. Nakamura and M. Tanaka, Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions, Cancer Res 64 (2004), 3215-3222.
144. R. S. Herbst, A. Onn and A. Sandler, Angiogenesis and lung cancer: Prognostic and therapeutic implications, J Clin Oncol 23 (2005), 3243-3256.
145. S. Patan, Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling, J Neuro-Oncol 50 (2000), 1-15.
146. K. Holmes, O. L. Roberts, A. M. Thomas andM. J. Cross, Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition, Cell Signal 19 (2007), 2003-2012.
147. L. Rydén, M. Stendahl, H. Jonsson, S. Emdin, N. O. Bengtsson and G. Landberg, Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response, Breast Cancer Res Treat 89 (2005), 135-143.
148. Z. Qu, S. Van Ginkel, A. M. Roy, L. Westbrook, M. Nasrin, Y. Maxuitenko, A. R. Frost, D. Carey, W. Wang, R. Li, W. E. Grizzle, J. V. Thottassery and F. G. Kern, Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors, Cancer Res 68(15) (2008), 6232-6240.
149. C. Charalambous, L. B. Pen, Y. S. Su, J. Milan, T. C. Chen and F. M. Hofman, Interleukin-8 differentially regulates migration of tumor-associated and normal human brain endothelial cells, Cancer Res 65(22) (2005), 10347-10354.
150. A. Li, S. Dubey, M. L. Varney, B. J. Dave and R. K. Singh, IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis, J Immunol 170(6) (2003), 3369-3376.
151. J. J. W. Chen, P. -L. Yao, A. Yuan, T. -M. Hong, C. -T. Shun, M. -L. Kuo, Y. -C. Lee and P. -C. Yang, Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer, Clin Cancer Res 9 (2003), 729-737.
152. M. H. Ali, S. A. Schlidt, N. S. Chandel, K. L. Hynes, P. A. Schumacker and B. L. Gewertz, Endothelial permeability and il-6 production during hypoxia: role of ROS in signal transduction, Am J Physiol Lung Cell Mol Physiol 277(21) (1999), L1057-L1065.
153. I. U. Schraufstatter, J. Chung and M. Burger, IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways, Am J Physiol Lung Cell Mol Physiol 280(6) (2001), L1094-L1103.
154. E. Sato, J. Fujimoto, H. Toyoki, H. Sakaguchi, S. M. Alam, I. Jahan and T. Tamaya, Expression of IP-10 related to angiogenesis in uterine cervical cancers, Br J Cancer 96 (2007), 1735-1739.
155. D. Wang, H. Wang, J. Brown, T. Daikoku, W. Ning, Q. Shi, A. Richmond, R. Strieter, S. K. Dey and R. N. DuBois, CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer, J ExpMed 203(4) (2006), 941-951.
156. M. Chow and H. Rubin, Clonal selection versus genetic instability as the driving force in neoplastic transformation, Cancer Res 60 (2000), 6510-6518.
157. L. Masramon, E. Vendrell, G. Tarafa, G. Capellà, R. Miró, M. Ribas and M. A. Peinado, Genetic instability and divergence of clonal populations in colon cancer cells in vitro, J Cell Science 119 (2006), 1477-1482.
158. D. Aldulaimi and J. Jankowski, Barrett's esophagus: an overview of themolecular biology, Dis Esophagus 12 (1999), 177-180.
159. I. Ferrando, J. Ferrando, G. Reig, P. Navarro, A. Llombart, M. Minquez, F. Mora and A. Benages, Barrett's esophagus, markers to distinguish risk groups, Rev Esp Enferm Dig 90 (1998), 431-440.
160. S. S. Coughlin, M. J. Khoury and K. K. Steinberg, BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives, AmJ Prev Med 16 (1999), 91-98.
161. T. R. Rebbeck, P. W. Kantoff, K. Krithivas, S. Neuhausen, M. A. Blackwood, A. K. Godwin, M. B. Dalyl, S. A. Narod, J. E. Garber, H. T. Lynch, B. L. Weber and M. Brown, Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat, Am J Hum Genet 64 (1999), 1371-1377.
162. Cancer Risks in BRCA2 Mutation Carriers. The Breast Cancer Linkage Consortium, J Natl Cancer Inst 91(15) (1999), 1310-1316.
163. W. Doerfler, The insertion of foreign DNA into mammalian genomes and its consequences: a concept in oncogenesis, Adv Cancer Res 66 (1995), 313-344.
164. D. Sidransky, Nucleic acid-based methods for the detection of cancer, Science 278 (1997), 1054-1059.
165. D. E. Henson, S. Srivastava and B. S. Kramer, Molecular and genetic targets in early detection, Curr Opin Oncol 11 (1999), 419-425.
166. S. A. Ahrendt and D. Sidransky, The potential of molecular screening, Surg Oncol Clin N Am 8 (1999), 641-656.
167. N. Jhala, D. Jhala, S. M. Vickers, I. Eltoum, S. K. Batra, U. Manne, M. Eloubeidi, J. J. Jones and W. E. Grizzle, Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. A model for translational research application, Am J Clinl Pathol 126(4) (2006), 572-579.
168. S. A. Optenberg and I. M. Thompson, Economics of screening for carcinoma of the prostate, Urol Clin North Am 17 (1990), 719-737.
169. H. K. Roy, V. Turzhitsky, Y. L. Kim, M. J. Goldberg, J. P. Muldoon, Y. Liu, R. E. Brand, C. Hall, N. Hasabou, M. Jameel and V. Backman, Spectral slope from the endoscopicallynormal mucosa predicts concurrent colonic neoplasia: a pilot ex-vivo clinical study, Dis Colon Rectum 51(9) (2008), 1381-1386.
170. H. K. Roy, A. Gomes, V. Turzhitsky, M. J. Goldberg, J. Rogers, S. Roderman, K. L. Young, A. Kromine, R. E. Brand, M. Jameel, P. Vaikl, N. Hasabou and V. Backman, Spectroscopic microvascular blood detection from the endoscopically normal colonic mucosa: biomarker for neoplasia risk, Gastroenterology 135(4) (2008), 1069-1078.
171. H. Subramanian, H. K. Roy, P. Pradhan, M. J. Goldberg, J. Muldoon, R. E. Brand, C. Sturgis, T. Hensing, D. Ray, A. Bogojevic, J. Mohammed, J. S. Chang and V. Backman, Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy, Cancer Res 69(13) (2009), 5357-5363.
172. H. K. Roy, V. Turzhitsky, Y. Kim, M. J. Goldberg, P. Watson, J. D. Rogers, A. J. Gomes, A. Kromine, R. E. Brand, M. Jameel, A. Bogovejic, P. Pradhan and V. Backman, Association between rectal optical signatures and colonic neoplasia: potential applications for screening, Cancer Res 69(10) (2009), 4476-4483.
173. S. Kvinnsland, Serum tumour markers in clinical practice. Some general aspects, Scand J Clin Lab Invest Suppl 206 (1991), 6-11.
174. N. E. Morton and A. E. Collins, Statistical and genetic aspects of quality control for DNA identification, Electrophoresis 16 (1995), 1670-1677.
175. F. P. Perera, R. M. Santella, D. Brenner, T. L. Young and I. B. Weinstein, Application of biological markers to the study of lung cancer causation and prevention, IARC Sci Publ 89 (1988), 451-459.
176. W. E. Grizzle, O. J. Semmes, W. Bigbee, L. Zhu, G. Malik, D. K. Oelschlager, B. Manne and U. Manne, The need for the review and understanding of SELDI/MALDI mass spectroscopy data prior to analysis, Cancer Informatics 1(1) (2005), 86-97.
177. D. McLerran, W. E. Grizzle, Z. Feng, W. L. Bigbee, L. L. Banez, L. H. Cazares, D. W. Chan, J. Diaz, E. Izbicka, J. Kagan, D. F. Malehon, G. Malik, D. Oelschlager, A. Partin, T. Randolph, N. Rosenzweig, S. Srivastava, S. Srivastava, I. M. Thompson, M. Thornquist, D. Troyer, Y. Yasui, Z. Zhang, L. Zhu and O. J. Semmes, Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias, Clin Chem 54(1) (2008), 44-52.
178. S. M. Lippman and W. K. Hong, 13-cis-retinoic acid and cancer chemoprevention, J Natl Cancer Inst Monogr 13 (1992), 111-115.
179. S. M. Lippman, G. L. Clayman, M. H. Huber et al. , Biology and reversal of aerodigestive tract carcinogenesis, Cancer Treat Res 74 (1995), 89-115.
180. S. Srivastava and B. S. Kramer, Genetics of lung cancer: implications for early detection and prevention, Cancer Treat Res 72 (1995), 91-110.
181. S. Srivastava and S. C. Rossi, Early detection research program at the NCI, Int J Cancer 69 (1996), 35-37.
182. W. K. Hong and S. M. Lippman, Cancer chemoprevention, J Natl Cancer Inst Monogr 17 (1995), 49-53.
183. M. S. Pepe, R. Etzioni, Z. Feng, J. D. Potter, M. L. Thompson, M. Thornquist, M. Winget and Y. Yasui, Phases of biomarker development for early detection of cancer, J Natl Cancer Inst 93(14) (2001), 1054-1061.
184. A. Steg,W. Wang, C. Blanquicett, J. M. Grunda, I. A. Eltoum, K. Wang, D. J. Buchsbaum, S. W. Vickers, S. Russo, R. B. Diasio, A. R. Frost, A. F. LoBuglio, W. E. Grizzle and M. R. Johnson, Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array, J Mol Diagn 8 (2006), 76-83.
185. A. Steg, S. M. Vickers, M. Eloubeidi, W. Wang, I. A. Eltoum, W. E. Grizzle, M. W. Saif, A. F. Lobuglio, A. R. Frost andM. R. Johnson, Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies, Diagn Mol Pathol 16(4) (2007), 229-237.
186. J. Asad, A. F. Jacobson, A. Estabrook, S. R. Smith, S. K. Boolbol, S. M. Feldman, M. P. Osborne, K. Boachie-Adjei, W. Twardzik and P. I. Tartter, Does oncotypeDXrecurrence score affect the management of patients with early-stage breast cancer? Am J Surg 196(4) (2008), 527-529.
187. K. Albain, W. Barlow, S. Shak et al. , Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, estrogen-receptorpositive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol 11(1) (2010), 55-65.
188. M. Cronin, C. Sangli, M. -L. Liu, M. Pho, D. Dutta, A. Nguyen, J. Jeong, J. Wu, K. C. Lagone and D. Watson, Analytical validation for the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer, Clin Chem 53(6) (2007), 1084-1091.
189. V. Katkoori, X. Jia, C. Shanmugam, W. Wan, S. Meleth, H. Bumpers, W. Grizzle and U. Manne, Prognostic Significance of p53 Codon 72 Polymorphism Differs with Race in Colorectal Adenocarcinoma, Clin Cancer Res 15(7) (2009), 2406-2416.
190. E. R. Gamazon, W. Zhang, A. Konkashbaev, S. Duan, E. O. Kistner, D. L. Nicolae, M. E. Dolan and N. J. Cox, SCAN: SNP and copy number annotation, Bioinformatics 26(2) (2010), 259-262.
191. W. E. Grizzle, S. Srivastava and U. Manne, Translational pathology of neoplasia, Cancer Biomark 9 (2011), 7-20.